The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors

Jonathan R. Strosberg, Thorvardur R. Halfdanarson, Andrew M. Bellizzi, Jennifer A Chan, Joseph S. Dillon, Anthony P. Heaney, Pamela L. Kunz, Thomas M. O'Dorisio, Riad Salem, Eva Segelov, James R. Howe, Rodney F. Pommier, Kari Brendtro, Mohammad A. Bashir, Simron Singh, Michael C. Soulen, Laura Tang, Jerome S. Zacks, James C. Yao, Emily K. Bergsland

Research output: Contribution to journalArticleOtherpeer-review

162 Citations (Scopus)


There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patientswith refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated 177Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut). Based on these and other advances, the North American Neuroendocrine Tumor Society convened a multidisciplinary panel of experts with the goal of updating consensus-based guidelines for evaluation and treatment of midgut NETs. The medical aspects of these guidelines (focusing on systemic treatment, nonsurgical liver-directed therapy, and postoperative surveillance) are summarized in this article. Surgical guidelines are described in a companion article.

Original languageEnglish
Pages (from-to)707-714
Number of pages8
Issue number6
Publication statusPublished - 2017


  • Medical management
  • Midgut NETs
  • Neuroendocrine tumor

Cite this